Diamyd Medical AB (OSTO:DMYD B) Total Liabilities : kr75.40 Mil (As of May. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Total Liabilities?

Diamyd Medical AB's Total Liabilities for the quarter that ended in May. 2025 was kr75.40 Mil.

Diamyd Medical AB's quarterly Total Liabilities increased from Nov. 2024 (kr66.78 Mil) to Feb. 2025 (kr69.35 Mil) and increased from Feb. 2025 (kr69.35 Mil) to May. 2025 (kr75.40 Mil).

Diamyd Medical AB's annual Total Liabilities increased from Aug. 2022 (kr22.15 Mil) to Aug. 2023 (kr36.41 Mil) and increased from Aug. 2023 (kr36.41 Mil) to Aug. 2024 (kr71.12 Mil).

Diamyd Medical AB Total Liabilities Historical Data

The historical data trend for Diamyd Medical AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Total Liabilities Chart

Diamyd Medical AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Total Liabilities

Get a 7-Day Free Trial

17.28

12.18

22.15

36.41

71.12

Diamyd Medical AB Quarterly Data
	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25
Total Liabilities	Get a 7-Day Free Trial															52.75	71.12	66.78	69.35	75.40

Diamyd Medical AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Diamyd Medical AB's Total Liabilities for the fiscal year that ended in Aug. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	40.025	+	(30.672	+	0.00099999999999584
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0.42	+	0)
	=	71.12

Total Liabilities	=	Total Assets (A: Aug. 2024 )	-	Total Equity (A: Aug. 2024 )
	=	217.038	-	145.92
	=	71.12

Diamyd Medical AB's Total Liabilities for the quarter that ended in May. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	29.655	+	(0	+	45.551
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0.192	+	0)
	=	75.40

Total Liabilities	=	Total Assets (Q: May. 2025 )	-	Total Equity (Q: May. 2025 )
	=	400.069	-	324.671
	=	75.40

Diamyd Medical AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

DYMDF:USA

Address

Kungsgatan 29, Stockholm, SWE, SE-111 56

Website

https://www.diamyd.com

Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines